Asia's largest drug maker, Takeda Pharmaceutical Co.'s stock has sunk after the company scrapped development of a diabetes drug after failing to show the medicine's benefits outweighed its risks. Takeda now had one less possible drug it can use to replace Actos, once the world's best selling diabetes medicine and buffer a decline in sales from other companies.